Nucleic acid underexpressed in melanoma
View Patent ↗The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
1. A method for the diagnosis of melanoma comprising:
(a) identifying a patient suspected of having melanoma; and
(b) detecting expression of SEQ ID NO: 23 in a test sample from said patient, wherein lower expression of the SEQ ID NO: 23 in said test sample as compared to a normal control sample indicates the presence of neoplastic disease.
2. The method of claim 1 , wherein the test sample and control sample are tissue from skin.
3. The method of claim 1 , wherein the expression of the SEQ ID NO: 23 is detected by a nucleic acid probe which hybridizes to:
(a) a nucleic acid sequence of SEQ ID NO:23;
(b) the coding sequence of the nucleic acid sequence of SEQ ID NO:23; or
(c) the coding sequence of the cDNA deposited under ATCC accession number 209902.
4. The method of claim 3 , wherein said hybridization occurs under stringent conditions comprising 50% formamide, 5×SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5× Denhardt's solution, sonicated salmon sperm DNA (50 μg/ml), 0.1% SDS, and 10% dextran sulfate at 42° C., with washes at 42° C. in 0.2×SSC (sodium chloride/sodium citrate) and 50% formamide at 55° C., followed by a high-stringency wash consisting of 0.1×SSC containing EDTA at 55° C.
5. The method of claim 1 , wherein the detection of the expression of the SEQ ID NO: 23 in the test sample is detected using a method selected from the group consisting of PCR, Northern analysis, Southern analysis, and in situ hybridization.